Matches in SemOpenAlex for { <https://semopenalex.org/work/W2779473033> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2779473033 abstract "Background: Non-small cell lung cancer (NSCLC) is one of the most studied cancers in cancer immunotherapy. Immune checkpoint inhibitors (ICIs) have unique immune related adverse effects. However, little is known about infectious diseases occurring during ICI treatment. Aims and Objectives: To examine the incidence and risk factors of infectious diseases in NSCLC patients receiving ICIs. Methods: We retrospectively reviewed NSCLC patients who received nivolumab, one of the ICIs, at National Hospital Organization Kyoto Medical Center and Kyoto University Hospital between December 2015 and November 2016. We counted all infectious diseases, occurring after initiation of nivolumab until 6 months after discontinuation. Results: Eighty-four NSCLC patients received nivolumab during the observational period. Of 84 patients, 20 (23.8%) patients developed an infectious disease. Fifteen patients (pneumonia, 9; lung abscess, 1; bloodstream infection, 2; skin infection, 2; tuberculosis, 1), two patients (Aspergillus, 1; Trichophyton, 1) and three patients (Zoster, 1; influenza, 2) developed bacterial, fungal and viral infection, respectively. There were no significant differences in characteristics, number of prior chemotherapies and nivolumab between patients with and without infection. Of 20 patients with infection, 10 (50%) had a history of steroid use during nivolumab treatment. However, there was no significant difference in corticosteroid use between patients with and without infection (50% vs. 56%, P=0.62). Conclusion: Incidence of infectious diseases was relatively high in patients with nivolumab treatment. ICI has a potential risk for infectious disease regardless of steroid use." @default.
- W2779473033 created "2018-01-05" @default.
- W2779473033 creator A5009156959 @default.
- W2779473033 creator A5033969315 @default.
- W2779473033 creator A5048538074 @default.
- W2779473033 creator A5062985377 @default.
- W2779473033 creator A5084313756 @default.
- W2779473033 creator A5090487149 @default.
- W2779473033 date "2017-09-01" @default.
- W2779473033 modified "2023-09-24" @default.
- W2779473033 title "Emerging concern of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy" @default.
- W2779473033 doi "https://doi.org/10.1183/1393003.congress-2017.oa1478" @default.
- W2779473033 hasPublicationYear "2017" @default.
- W2779473033 type Work @default.
- W2779473033 sameAs 2779473033 @default.
- W2779473033 citedByCount "3" @default.
- W2779473033 countsByYear W27794730332019 @default.
- W2779473033 countsByYear W27794730332020 @default.
- W2779473033 crossrefType "proceedings-article" @default.
- W2779473033 hasAuthorship W2779473033A5009156959 @default.
- W2779473033 hasAuthorship W2779473033A5033969315 @default.
- W2779473033 hasAuthorship W2779473033A5048538074 @default.
- W2779473033 hasAuthorship W2779473033A5062985377 @default.
- W2779473033 hasAuthorship W2779473033A5084313756 @default.
- W2779473033 hasAuthorship W2779473033A5090487149 @default.
- W2779473033 hasConcept C120665830 @default.
- W2779473033 hasConcept C121332964 @default.
- W2779473033 hasConcept C121608353 @default.
- W2779473033 hasConcept C126322002 @default.
- W2779473033 hasConcept C197934379 @default.
- W2779473033 hasConcept C2776256026 @default.
- W2779473033 hasConcept C2777701055 @default.
- W2779473033 hasConcept C2778715236 @default.
- W2779473033 hasConcept C2779134260 @default.
- W2779473033 hasConcept C2780030458 @default.
- W2779473033 hasConcept C524204448 @default.
- W2779473033 hasConcept C61511704 @default.
- W2779473033 hasConcept C71924100 @default.
- W2779473033 hasConceptScore W2779473033C120665830 @default.
- W2779473033 hasConceptScore W2779473033C121332964 @default.
- W2779473033 hasConceptScore W2779473033C121608353 @default.
- W2779473033 hasConceptScore W2779473033C126322002 @default.
- W2779473033 hasConceptScore W2779473033C197934379 @default.
- W2779473033 hasConceptScore W2779473033C2776256026 @default.
- W2779473033 hasConceptScore W2779473033C2777701055 @default.
- W2779473033 hasConceptScore W2779473033C2778715236 @default.
- W2779473033 hasConceptScore W2779473033C2779134260 @default.
- W2779473033 hasConceptScore W2779473033C2780030458 @default.
- W2779473033 hasConceptScore W2779473033C524204448 @default.
- W2779473033 hasConceptScore W2779473033C61511704 @default.
- W2779473033 hasConceptScore W2779473033C71924100 @default.
- W2779473033 hasLocation W27794730331 @default.
- W2779473033 hasOpenAccess W2779473033 @default.
- W2779473033 hasPrimaryLocation W27794730331 @default.
- W2779473033 hasRelatedWork W2160834915 @default.
- W2779473033 hasRelatedWork W2350042368 @default.
- W2779473033 hasRelatedWork W2513360745 @default.
- W2779473033 hasRelatedWork W2566940676 @default.
- W2779473033 hasRelatedWork W2736166064 @default.
- W2779473033 hasRelatedWork W2756149823 @default.
- W2779473033 hasRelatedWork W2762039295 @default.
- W2779473033 hasRelatedWork W2762537615 @default.
- W2779473033 hasRelatedWork W2777401485 @default.
- W2779473033 hasRelatedWork W2780393431 @default.
- W2779473033 hasRelatedWork W2903883219 @default.
- W2779473033 hasRelatedWork W2980012328 @default.
- W2779473033 hasRelatedWork W2982278711 @default.
- W2779473033 hasRelatedWork W2986012696 @default.
- W2779473033 hasRelatedWork W2994841801 @default.
- W2779473033 hasRelatedWork W2996162850 @default.
- W2779473033 hasRelatedWork W3004861383 @default.
- W2779473033 hasRelatedWork W3028523524 @default.
- W2779473033 hasRelatedWork W3135571623 @default.
- W2779473033 hasRelatedWork W3172340099 @default.
- W2779473033 isParatext "false" @default.
- W2779473033 isRetracted "false" @default.
- W2779473033 magId "2779473033" @default.
- W2779473033 workType "article" @default.